Brian Johnson, one of the world's most prominent advocates for radical life extension and the creator of the Blueprint project, has faced a serious medical challenge. The 48-year-old American entrepreneur publicly announced a diagnosis of autoimmune gastritis (AIG). This condition, in which the immune system attacks the stomach's own parietal cells, calls into question the effectiveness of his long-term experiment to "reset" his biological age.

A Hidden System Failure: 11 Years Without Symptoms

The situation regarding Johnson's diagnosis is notable because the pathology developed covertly. According to the millionaire himself, markers of the disease were present in his test results for 11 years. The primary indicator was a consistently low level of ferritin and iron in the blood serum. For a long time, doctors could not find the cause of the anomaly until a comprehensive examination, including endoscopy and biopsy of the gastric mucosa, confirmed the autoimmune nature of the process.

AIG is an incurable chronic disease affecting 2–5% of the world's population. Its main danger lies in the destruction of cells that produce hydrochloric acid and intrinsic factor. This leads to impaired absorption of iron and vitamin B12, which in the long run can lead to pernicious anemia and neurological dysfunctions. Furthermore, there is a long-term risk of developing neuroendocrine cell hyperplasia and gastric adenocarcinoma.

The Price of Biohacking: Supplements and Plasma

Gastroenterology experts do not rule out that the manifestation of the autoimmune process was triggered by the aggressive methodologies used within the Blueprint project. The daily intake of more than 100 types of dietary supplements (supplements) creates a colossal chemical and mechanical load on the mucous membrane of the gastrointestinal tract.

In addition, Johnson's treatment protocol included radical procedures, such as infusions of plasma from third-party donors. Specialists believe that such a load could have caused an atypical and hyperactive response from the immune system, causing it to attack the body's own tissues.

Combat Strategy: From Standard Therapy to Organoids

The standard treatment protocol for AIG is exclusively replacement-based: regular injections of vitamin B12 and iron preparations to alleviate micronutrient deficiency. However, the Blueprint team does not intend to stop at supportive therapy. Johnson plans to employ cutting-edge scientific approaches to achieve remission or even regeneration of damaged tissues.

The entrepreneur has identified three key vectors in the priority treatment directions:

  • Immune cell therapy: Sequencing the patient's individual immune cells to develop a personalized method for reducing their auto-aggressive potential.
  • Use of cellular models: Growing organoids in the laboratory — miniature three-dimensional models of Brian's stomach — to test experimental drugs without risk to the subject's health.
  • Nutritional status correction: Switching to parenteral administration of critically important trace elements, allowing bypass of damaged gastrointestinal barriers.

Despite the seriousness of the diagnosis, clinical data indicates that with timely detection of deficiency and adequate therapy, the development of severe complications can be prevented, maintaining life expectancy at average population levels. For Johnson, this case has become a harsh reminder that even the most technological methods of intervening in biological processes can have unpredictable consequences.